Settlement of Valsartan Lawsuit Nears for Some
Plaintiffs sued Hetero, the manufacturer of valsartan, a generic blood pressure medication, because it was contaminated with carcinogens, and they alleged it caused cancer. The lawsuits were consolidated in 2019. These cases are coming closer to settlement. Recently, the United States District Judge Renée M. Bumb who is presiding over the multidistrict litigation ordered both sides to finalize a settlement agreement in all of the plaintiff groups; there are three groups, one for personal injury, another for economic loss, and still another for medical monitoring. The deadline was June 30. If you were harmed by Valsartan, you should call the seasoned Chicago-based lawyers of Moll Law Group. Billions have been recovered in cases with which we’ve been involved.
Contact Moll Law Group About Your Valsartan Cancer Claim
Valsartan, manufactured safely by Novartis Pharmaceuticals Corp. under the brand name Diovan, functions by relaxing a patient’s blood vessels. This improves flow and reduces pressure. When the patent expired, various generic manufacturers in China and India began selling the drug, which they made with a different manufacturing process. The U.S. Food and Drug Administration investigated claims that drugs manufactured overseas contained NDMA or N-nitrosodimethylamine or NDEA (N-nitrosodimethylamine).
In 2018, the generic Valsartan was recalled around the world because of its unacceptable levels of carcinogenic toxins. Many patients, including around 3 million Americans, had not known they were taking contaminated drugs that could seriously harm them.